1. Home
  2. WHG vs SPRO Comparison

WHG vs SPRO Comparison

Compare WHG & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Westwood Holdings Group Inc

WHG

Westwood Holdings Group Inc

HOLD

Current Price

$19.45

Market Cap

189.7M

Sector

Finance

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.23

Market Cap

156.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WHG
SPRO
Founded
1983
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
189.7M
156.3M
IPO Year
2002
2017

Fundamental Metrics

Financial Performance
Metric
WHG
SPRO
Price
$19.45
$1.23
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
14.5K
1.7M
Earning Date
04-30-2026
05-13-2026
Dividend Yield
3.58%
N/A
EPS Growth
203.85
111.81
EPS
0.25
N/A
Revenue
$97,762,000.00
$66,802,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$300.00
P/E Ratio
$77.08
N/A
Revenue Growth
3.21
39.24
52 Week Low
$14.70
$1.08
52 Week High
$20.97
$3.08

Technical Indicators

Market Signals
Indicator
WHG
SPRO
Relative Strength Index (RSI) 52.98 31.65
Support Level $18.87 $1.10
Resistance Level $20.50 $1.28
Average True Range (ATR) 0.63 0.07
MACD -0.05 0.04
Stochastic Oscillator 54.17 48.57

Price Performance

Historical Comparison
WHG
SPRO

About WHG Westwood Holdings Group Inc

Westwood Holdings Group Inc manages investment assets and provides services for clients through subsidiaries. It operates its business through the Advisory and Trust segments. Its Advisory segment provides investment advisory services to corporate retirement plans, public retirement plans, endowments, foundations, individuals and the Westwood Funds, as well as investment sub-advisory services to mutual funds and its trust segment. The Trust segment offers trust and custodial services to its clients and its advisory segment sponsors common trust funds to institutions and high net-worth individuals. It generates maximum revenue from the Advisory segment. Geographically, it derives a majority of its revenue from the United States, and also has its presence in Canada.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: